[CAS NO. 219685-50-4] Eculizumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [219685-50-4]

Catalog

AS975773

Brand

Arctom Scientific

CAS

219685-50-4

DESCRIPTION [219685-50-4]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Eculizumab]

For research use only. We do not sell to patients.

Summary

Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5 . Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01399593	Alexion Pharmaceuticals	Antibody Mediated Rejection	November 2, 2011	Phase 2
NCT04288713	Hudson Medical	Coronavirus
NCT00122317	Alexion Pharmaceuticals	Paroxysmal Hemoglobinuria, Nocturnal	May 2005	Phase 3
NCT00098280	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Hemoglobinuria, Paroxysmal	December 2004	Phase 3
NCT01221181	Columbia University\|Alexion Pharmaceuticals	Dense Deposit Disease\|Membranoproliferative Glomerulonephritis	July 2010	Phase 1
NCT04103489	Johns Hopkins University\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	HELLP Syndrome (HELLP), Third Trimester\|Complement Abnormality\|Morbidity;Newborn\|Maternal Injury\|Preeclampsia Severe	February 23, 2021	Phase 1
NCT04558918	Novartis Pharmaceuticals\|Novartis	Paroxysmal Nocturnal Hemoglobinuria (PNH)	January 25, 2021	Phase 3
NCT01303952	University Hospital, Essen\|Alexion Pharmaceuticals	Cold Agglutinin Disease	January 2011	Phase 2
NCT03818607	Amgen	Paroxysmal Nocturnal Hemoglobinuria	April 24, 2019	Phase 3
NCT01410916	Alexion Pharmaceuticals	Shiga-like Toxin-producing Escherichia Coli	July 2011	Phase 2\|Phase 3
NCT01919346	Heeger, Peter, M.D.\|Alexion Pharmaceuticals\|Icahn School of Medicine at Mount Sinai	Delayed Graft Function\|Kidney Transplantation\|Complement Activity	August 2013	Phase 2
NCT04320602	Alexion Pharmaceuticals	Paroxysmal Nocturnal Hemoglobinuria	March 26, 2021	Phase 4
NCT00122304	Alexion Pharmaceuticals	Hemoglobinuria, Paroxysmal	December 2004	Phase 3
NCT03722329	Samsung Bioepis Co., Ltd.	Healthy	November 13, 2018	Phase 1
NCT01997229	Alexion Pharmaceuticals	Refractory Generalized Myasthenia Gravis	December 2013	Phase 3
NCT00844844	Alexion Pharmaceuticals	Atypical Hemolytic Uremic Syndrome	May 2009	Phase 2
NCT00844545	Alexion Pharmaceuticals	Atypical Hemolytic Uremic Syndrome	May 2009	Phase 2
NCT00438789	Alexion Pharmaceuticals	Hemoglobinuria, Paroxysmal
NCT04155424	Alexion Pharmaceuticals	Neuromyelitis Optica\|Neuromyelitis Optica Spectrum Disorder	January 14, 2020	Phase 2\|Phase 3
NCT01403389	Schroppel, Bernd, M.D.\|Alexion Pharmaceuticals	Delayed Function of Renal Transplant	December 1, 2011	Phase 2
NCT01895127	Brigham and Women´s Hospital\|Alexion Pharmaceuticals	Antibody-mediated Rejection\|Humoral Rejection	November 2013	Phase 2
NCT04355494	Alexion Pharmaceuticals	COVID-19\|Pneumonia, Viral\|Acute Lung Injury+Acute Respiratory Distress Syndrome (ARDS)
NCT00727194	Alexion Pharmaceuticals	Myasthenia Gravis	October 2008	Phase 2
NCT00670774	Mark Stegall\|Alexion Pharmaceuticals\|Mayo Clinic	Kidney Transplant	March 2008	Phase 1\|Phase 2
NCT00935883	Philip J. Rosenfeld, MD, PhD\|Alexion Pharmaceuticals\|University of Miami	Age-Related Macular Degeneration	July 2009	Phase 2
NCT04079257	Radboud University Medical Center	Paroxysmal Nocturnal Hemoglobinuria\|Eculizumab\|PK-PD	February 23, 2021
NCT03468140	Yale University\|Ochsner Health System\|Alexion Pharmaceuticals	End Stage Liver Disease	October 1, 2021	Early Phase 1
NCT02145182	Alexion Pharmaceuticals\|CTI Clinical Trial and Consulting Services	Delayed Graft Function	August 21, 2014	Phase 2\|Phase 3
NCT01892345	Alexion Pharmaceuticals	Neuromyelitis Optica\|Neuromyelitis Optica Spectrum Disorder	April 11, 2014	Phase 3
NCT01757431	Alexion Pharmaceuticals	Atypical Hemolytic Uremic Syndrome (aHUS)	May 16, 2012	Phase 2
NCT04679103	AO GENERIUM	Paroxysmal Nocturnal Hemoglobinuria	May 3, 2018	Phase 3
NCT00130000	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Paroxysmal Hemoglobinuria, Nocturnal	August 9, 2005	Phase 3
NCT01756508	Russian Academy of Medical Sciences	End-Stage Renal Disease\|Kidney Failure\|Graft Reperfusion Injury	September 1, 2012	Phase 2
NCT02493725	Chiba University\|Japan Agency for Medical Research and Development	Gullain Barre Syndrome	July 2015	Phase 2
NCT00838513	Alexion Pharmaceuticals	Atypical Hemolytic Uremic Syndrome	July 2009	Phase 2
NCT03950804	Marmara University\|National Institute of Allergy and Infectious Diseases (NIAID)	CD55 - Cluster of Differentiation Antigen 55 Deficiency\|Primary Intestinal Lymphangiectasis\|Protein-Losing Enteropathies\|Complement Regulatory Factor Defect	June 15, 2018
NCT02298933	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Thrombocytopenia\|Alloimmune Platelet Refractoriness	November 21, 2014	Phase 2
NCT01579838	Hadassah Medical Organization	Chronic Hemolysis	February 2012	Phase 1\|Phase 2
NCT04346797	Assistance Publique - Hôpitaux de Paris	SARS-CoV-2\|COVID19	April 16, 2020	Phase 2
NCT04752566	Alexion Pharmaceuticals	Guillain-Barre Syndrome	March 8, 2021	Phase 3
NCT05131204	Regeneron Pharmaceuticals	Paroxysmal Nocturnal Hemoglobinuria	March 31, 2022	Phase 3
NCT00904826	Mayo Clinic\|Alexion Pharmaceuticals	Neuromyelitis Optica\|Devic´s Disease	April 2009	Phase 1\|Phase 2
NCT02093533	Mario Negri Institute for Pharmacological Research\|Alexion Pharma Italy s.r.l.	Membranoproliferative Glomerulonephritis	March 2014	Phase 2
NCT01106027	Mayo Clinic\|Alexion Pharmaceuticals	Kidney Transplant	March 2010	Phase 1\|Phase 2
NCT03759366	Alexion Pharmaceuticals	Myasthenia Gravis\|Myasthenia Gravis, Juvenile Form\|Myasthenia Gravis, Generalized	December 21, 2018	Phase 3
NCT05116774	BioCryst Pharmaceuticals	Paroxysmal Nocturnal Hemoglobinuria (PNH)	December 6, 2021	Phase 2
NCT02205541	University Hospital, Toulouse	Hemolytic Uremic Syndrome of Childhood	June 2015	Phase 3
NCT02013037	Cedars-Sinai Medical Center\|Alexion Pharmaceuticals	Antibody-mediated Rejection\|Hyperacute Rejection of Cardiac Transplant\|Left Ventricular Dysfunction\|Cardiac Allograft Vasculopathy\|Heart Graft Dysfunction	November 2012	Phase 3
NCT00122330	Alexion Pharmaceuticals	Hemoglobinuria, Paroxysmal	October 2004	Phase 3
NCT01192399	Alexion Pharmaceuticals	Paroxysmal Nocturnal Hemoglobinuria	November 2007	Phase 2
NCT03472885	Alexion Pharmaceuticals\|Achillion, a wholly owned subsidiary of Alexion	Paroxysmal Nocturnal Hemoglobinuria (PNH)	May 8, 2018	Phase 2
NCT04432584	Hoffmann-La Roche\|Chugai Pharmaceutical	Paroxysmal Nocturnal Hemoglobinuria	September 30, 2020	Phase 3
NCT03056040	Alexion Pharmaceuticals	Paroxysmal Nocturnal Hemoglobinuria (PNH)	June 5, 2017	Phase 3
NCT01275287	University of North Carolina, Chapel Hill\|Alexion Pharmaceuticals\|National Institutes of Health (NIH)\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	May 2011	Phase 2
NCT02604420	Weill Medical College of Cornell University	Thrombotic Microangiopathy\|Disorder Related to Bone Marrow Transplantation	September 2014
NCT04802083	Alexion Pharmaceuticals	Covid19
NCT02003144	Alexion Pharmaceuticals	Neuromyelitis Optica\|Neuromyelitis Optica Spectrum Disorder	January 12, 2015	Phase 3
NCT04725812	Cedars-Sinai Medical Center\|Alexion Pharmaceuticals	Preeclampsia\|Severe Preeclampsia\|Eculizumab\|HELLP\|HELLP Syndrome\|HELLP Syndrome Second Trimester\|Pregnancy Related\|AHUS\|PNH\|Complement Regulatory Factor Defect\|Complement Abnormality\|HELLP Syndrome Third Trimester	September 13, 2021	Phase 2
NCT02029378	NHS Greater Glasgow and Clyde\|University of Glasgow	Gullian Barre Syndrome	September 2014	Phase 2
NCT01327573	Sanjay Kulkarni\|Alexion Pharmaceuticals\|Yale University	Kidney; Complications, Allograft	March 2011	Phase 1
NCT01194973	Alexion Pharmaceuticals	Atypical Hemolytic-Uremic Syndrome	July 2010	Phase 2
NCT04058158	Samsung Bioepis Co., Ltd.	Paroxysmal Nocturnal Hemoglobinuria	August 7, 2019	Phase 3
NCT02727608	Uppsala University	Diabetes Mellitus	May 15, 2016	Phase 2
NCT04859608	University Hospital, Tours\|Centre Hospitalier Universitaire, Amiens\|University Hospital, Angers\|Centre Hospitalier Universitaire de Besancon\|University Hospital, Caen\|Centre Hospitalier of Chartres\|Nantes University Hospital\|University of Nancy\|Poitiers University Hospital\|Rennes University Hospital\|University Hospital, Rouen\|University Hospital, Strasbourg, France\|Centre Hospitalier Universitaire de Nice\|Hôpital Necker-Enfants Malades\|Tenon Hospital, Paris\|University Hospital, Lille\|Reims University Hospital\|University Hospital, Clermont-Ferrand\|Assistance Publique Hopitaux De Marseille\|Hospices Civils de Lyon	Hemolytic-Uremic Syndrome, Atypical	November 1, 2021	Phase 4
NCT00112983	Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI)	Leukemia	November 2004	Phase 3
NCT04935177	Hansa Biopharma AB	Kidney Transplantation in Highly Sensitized Patients	October 14, 2021	Phase 3
NCT00485576	Alexion Pharmaceuticals	Allergic Asthma	September 2007	Phase 2
NCT03518203	Children´s Hospital Medical Center, Cincinnati	Thrombotic Microangiopathies\|Atypical Hemolytic Uremic Syndrome\|Multiple Organ Dysfunction Syndrome	August 3, 2018	Phase 2
NCT04434092	Hoffmann-La Roche\|Chugai Pharmaceutical	Paroxysmal Nocturnal Hemoglobinuria	October 8, 2020	Phase 3
NCT01567085	Alexion Pharmaceuticals	Stage V Chronic Kidney Disease	August 29, 2012	Phase 2
NCT02574403	Nantes University Hospital	Atypical Hemolytic Uremic Syndrome	November 2015	Phase 4
NCT02614898	Alexion Pharmaceuticals	Atypical Hemolytic Uremic Syndrome	November 4, 2015
NCT01194804	Alexion Pharmaceuticals\|CMIC Co, Ltd. Japan	Paroxysmal Nocturnal Hemoglobinuria	April 2008	Phase 2
NCT02113891	Assistance Publique - Hôpitaux de Paris\|Institut National de la Santé Et de la Recherche Médicale, France\|Alexion Pharmaceuticals	Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation	February 2015	Phase 1\|Phase 2
NCT02301624	Alexion Pharmaceuticals	Refractory Generalized Myasthenia Gravis	November 12, 2014	Phase 3
NCT01095887	Mayo Clinic\|Alexion Pharmaceuticals	Kidney Transplant	May 2010	Phase 1\|Phase 2
NCT00844428	Alexion Pharmaceuticals	Atypical Hemolytic Uremic Syndrome	July 2009	Phase 2
NCT01193348	Alexion Pharmaceuticals	Atypical Hemolytic-Uremic Syndrome	September 2010	Phase 2
NCT00867932	Alexion Pharmaceuticals	Hemoglobinuria, Paroxysmal	October 2, 2009	Phase 4
NCT01029587	Johns Hopkins University	Antiphospholipid Antibody Syndrome\|End Stage Renal Disease	November 2009	Phase 2
NCT02946463	Alexion Pharmaceuticals	Paroxysmal Nocturnal Hemoglobinuria (PNH)	December 20, 2016	Phase 3

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Eline A Dubois,et al. Eculizumab. Br J Clin Pharmacol. 2009 Sep;68(3):318-9.